118 results
8-K
EX-99.1
PULM
Pulmatrix, Inc.
13 Aug 24
Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update
9:05am
), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease
8-K
EX-99.1
PULM
Pulmatrix, Inc.
29 May 24
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
8:45am
”) (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system … innovative particle engineering dry powder technology. In addition, the assumption of our lease and laboratory by MannKind helps extend our cash runway
8-K
EX-99.1
PULM
Pulmatrix, Inc.
15 May 24
Regulation FD Disclosure
9:00am
. (“Pulmatrix” or the “Company”) (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious … Technology
Our innovative particle engineering technology creates dry powder, which solves limitations of conventional inhaled technologies and expands
8-K
EX-99.1
PULM
Pulmatrix, Inc.
10 May 24
Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update
9:05am
, Inc. (“Pulmatrix” or the “Company”) (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address
8-K
EX-99.1
r9fit tvk
28 Mar 24
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
9:05am
8-K
EX-99.1
2w8 bjnryb6a67
8 Jan 24
Entry into a Material Definitive Agreement
9:00am
8-K
EX-99.1
xdyl hlsue4mkttt0yvf
9 Nov 23
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
9:05am
8-K
EX-99.1
le118baa3haq zp2d02c
10 Aug 23
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update
9:05am
8-K
EX-99.1
dfd03l zx9
11 Jul 23
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
9:05am
8-K
EX-99.1
sitys908az7
12 May 23
Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update
9:05am
8-K
EX-99.1
9zmwi9eo
30 Mar 23
Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update
9:05am
8-K
EX-99.1
8ijg37fdccnq xuka9
14 Nov 22
Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update
6:17am
8-K
EX-99.1
2ce1h
26 Sep 22
Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine
9:00am
8-K
EX-99.1
l0m2htpd xy56neu7
10 Aug 22
Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update
9:15am
8-K
EX-99.1
src5w7w4ezjn6
12 Jul 22
Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine
9:00am
8-K
EX-99.1
jfxkjjwgd jppp3t
12 May 22
Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update
9:15am
8-K
EX-10.1
nd887amwzxh
15 Apr 22
Departure of Directors or Certain Officers
4:11pm